Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire (REACT)

March 8, 2017 updated by: Cédric PENNETIER, Institut de Recherche pour le Developpement

Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire: Research on Vector Control Strategies

This study evaluates the benefit to use 1) insecticidal paints, 2) larvicides, 3) Ivermectin for both human and domestic animals and 4) strengthened Information, Education and Communication (IEC) strategy to complement the universal coverage with LLINs through a cluster randomized trial.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Insecticidal paint comprised of two organophosphates (OPs) and an Insect Growth Regulator (IGR). This tool targets adult mosquitoes that are resistant pyrethroids to reduce vector density.

Larvicide is a new formulation of Bacillus thuringiensis israelensis that will be implemented in major permanent breeding sites with the objective to reduce vector density.

Ivermectin will be injected to domestic animals in addition to the national campaign implemented in the study area which treats the whole population. Ivermectin reduces the survival of mosquito that blood feed on treated humans and animals.

Information, Education and Communication strategy aims to increase the adherence of the population to control tools available. Strengthening the IEC aims to increase the good use of long lasting nets.

Study Type

Interventional

Enrollment (Anticipated)

18000

Phase

  • Phase 3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 months to 20 years (ADULT, CHILD)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Must be an inhabitant of the villages included into the RCT
  • Aged from 6month old to 20 years old

Exclusion Criteria:

  • older than 20 year old

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Control
No intervention
EXPERIMENTAL: insecticidal paint
The insecticidal paint contains two organophosphates, chlorpyriphos(1.5%) and diazinon (1.5%), and an insect growth regulator (IGR),pyriproxyfen (0.063%), as active ingredients.
Device: Insecticidal paint
Houses will be painted with insecticidal paint
Other Names:
  • Inestfly 5A IGR
EXPERIMENTAL: Larvicides
The larvicide is a slow release formulation containing Bacillus thuringiensis Var Israelensis.
Device: Larvicide
Larval breeding sites will be treated with larvicide
EXPERIMENTAL: Ivermectin
This arm consists in an injectable dose of Ivermectin given to peri-domestic animals.
Biological: Ivermectin
Doses of Ivermectin will be injected to peri-domestic animals
EXPERIMENTAL: Information, Education, Communication
After a sociological study during the pre-intervention year, this arm will consist in a reinforced communication strategy relative to the nationwide current one
Behavioral: IEC
A reinforced information, education and communication strategy will be implemented.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Malaria incidence
Time Frame: continuous monitoring during 2 years
Malaria cases reported in local health system
continuous monitoring during 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Entomological Inoculation Rate
Time Frame: Every 8 weeks during 2 years
Number of infectious bites/personn
Every 8 weeks during 2 years
Malaria prevalence
Time Frame: Every 4 months during 2 years
% of positive blood smears among the population between 6 months to 20 years
Every 4 months during 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut de Recherche pour le Developpement

Collaborators

Institut de Recherche en Sciences de la Sante, Burkina Faso
Institut Pierre Richet

Investigators

  • Principal Investigator: Cédric Pennetier, PhD, Institut de Rehcerche pour le Développement

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2016

Primary Completion (ANTICIPATED)

October 1, 2017

Study Completion (ANTICIPATED)

April 1, 2019

Study Registration Dates

First Submitted

November 4, 2016

First Submitted That Met QC Criteria

March 7, 2017

First Posted (ACTUAL)

March 8, 2017

Study Record Updates

Last Update Posted (ACTUAL)

March 10, 2017

Last Update Submitted That Met QC Criteria

March 8, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • InstitutRD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malaria

Clinical Trials on Insecticidal paint

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe